Using the Promise of Sonodynamic Therapy in the Clinical Setting against Disseminated Cancers

Chemotherapy Research and Practice

Volumn 2015, Issue , 2015, Pages

  Trendowski, Matthew ^a  

^a SYRACUSE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C;

BLOOD BRAIN BARRIER; BLOOD VESSEL INJURY; BRAIN TUMOR; CANCER CELL; CANCER THERAPY; CELL MEMBRANE PERMEABILITY; CLINICAL EXAMINATION; DIAGNOSTIC IMAGING; DISSEMINATED CANCER; DRUG DELIVERY SYSTEM; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HYDRODYNAMICS; IN VIVO STUDY; MICROBUBBLE; MITOCHONDRIAL MEMBRANE; PINOCYTOSIS; PRIORITY JOURNAL; REVIEW; SONODYNAMIC THERAPY; TUMOR VASCULARIZATION; ULTRASOUND; ULTRASOUND THERAPY;

EID: 84970920518     PISSN: 20902107     EISSN: 20902115     Source Type: Journal    
DOI: 10.1155/2015/316015     Document Type: Review

References (113)

1. M. Trendowski, "The promise of sonodynamic therapy," Cancer and Metastasis Reviews, vol. 33, no. 1, pp. 143-160, 2014.
2. S.-I. Umemura, N. Yumita, and R. Nishigaki, "Enhancement of ultrasonically induced cell damage by a gallium-porphyrin complex, ATX-70," Japanese Journal of Cancer Research, vol. 84, no. 5, pp. 582-588, 1993.
3. K. Umemura, N. Yumita, R. Nishigaki, and S.-I. Umemura, "Sonodynamically induced antitumor effect of pheophorbide a," Cancer Letters, vol. 102, no. 1-2, pp. 151-157, 1996.
4. N. Yumita, S.-I. Umemura, N. Magario et al., "Sonodynamically-induced in vitro cell damage enhanced by adriamycin," Cancer Letters, vol. 121, no. 2, pp. 195-201, 1997.
5. N. Yumita, S.-I. Umemura, M. Kaneuchi et al., "Sonodynamically-induced cell damage with fluorinated anthracycline derivative, FAD104," Cancer Letters, vol. 125, no. 1-2, pp. 209-214, 1998.
6. I. Rosenthal, J. Z. Sostaric, and P. Riesz, "Sonodynamic therapy: a review of the synergistic effects of drugs and ultrasound," Ultrasonics Sonochemistry, vol. 11, no. 6, pp. 349-363, 2004.
7. W.-K. Bai, E. Shen, and B. Hu, "Induction of the apoptosis of cancer cell by sonodynamic therapy: a review," Chinese Journal of Cancer Research, vol. 24, no. 4, pp. 368-373, 2012.
8. M. Kuroki, K. Hachimine, H. Abe et al., "Sonodynamic therapy of cancer using novel sonosensitizers," Anticancer Research, vol. 27, no. 6, pp. 3673-3677, 2007.
9. S. Mitragotri, "Healing sound: the use of ultrasound in drug delivery and other therapeutic applications," Nature Reviews Drug Discovery, vol. 4, no. 3, pp. 255-260, 2005.
10. S. Thüroff, C. Chaussy, G. Vallancien et al., "High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study," Journal of Endourology, vol. 17, no. 8, pp. 673-677, 2003.
11. K. Ahrar, S. Matin, C. G. Wood et al., "Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes," Journal of Vascular and Interventional Radiology, vol. 16, no. 5, pp. 679-688, 2005.
12. J. R. Hecht, R. Bedford, J. L. Abbruzzese et al., "A phase I/II trial of intratumoral endoscopic ultrasound injection ofONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma," Clinical Cancer Research, vol. 9, no. 2, pp. 555-561, 2003.
13. P. Benedetti-Panici, G. Perniola, C. Marchetti et al., "Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: feasibility, compliance, and complications," International Journal of Gynecological Cancer, vol. 22, no. 6, pp. 1069-1074, 2012.
14. Z. Huang, "A review of progress in clinical photodynamic therapy," Technology in Cancer Research and Treatment, vol. 4, no. 3, pp. 283-293, 2005.
15. M. W. Miller, A. E. Luque, L. F. Battaglia, S. Mazza, and E. C. Everbach, "Biological and environmental factors affecting ultrasound-induced hemolysis in vitro: 1. HIV macrocytosis (cell size)," Ultrasound in Medicine and Biology, vol. 29, no. 1, pp. 77-91, 2003.
16. N. G. Lee, J. L. Berry, T. C. Lee et al., "Sonoporation enhances chemotherapeutic efficacy in retinoblastoma cells in vitro," Investigative Ophthalmology and Visual Science, vol. 52, no. 6, pp. 3868-3873, 2011.
17. Y. Zhou, J. Cui, and C. X. Deng, "Dynamics of sonoporation correlated with acoustic cavitation activities," Biophysical Journal, vol. 94, no. 7, pp. L51-L53, 2008.
18. Z. Fan, D. Chen, and C. X. Deng, "Improving ultrasound gene transfection efficiency by controlling ultrasound excitation of microbubbles," Journal of Controlled Release, vol. 170, no. 3, pp. 401-413, 2013.
19. K. Iwanaga, K. Tominaga, K. Yamamoto et al., "Local delivery system of cytotoxic agents to tumors by focused sonoporation," Cancer Gene Therapy, vol. 14, no. 4, pp. 354-363, 2007.
20. L.-F. Jin, F. Li, H.-P.Wang, F. Wei, P. Qin, and L.-F. Du, "Ultrasound targeted microbubble destruction stimulates cellular endocytosis in facilitation of adeno-associated virus delivery," International Journal of Molecular Sciences, vol. 14, no. 5, pp. 9737-9750, 2013.
21. M. Bazan-Peregrino, B. Rifai, R. C. Carlisle et al., "Cavitationenhanced delivery of a replicating oncolytic adenovirus to tumors using focused ultrasound," Journal of Controlled Release, vol. 169, no. 1-2, pp. 40-47, 2013.
22. R. Carlisle, J. Choi, M. Bazan-Peregrino et al., "Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound," Journal of the National Cancer Institute, vol. 105, no. 22, pp. 1701-1710, 2013.
23. D. R. Groothuis, "The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery," Neuro-Oncology, vol. 2, no. 1, pp. 45-49, 2000.
24. B. A. Chabner and D. L. Longo, Cancer Chemotherapy and Biotherapy: Principles and Practice, Lippincott Williams & Wilkins, 5th edition, 2011.
25. P. R. Lockman, R. K. Mittapalli, K. S. Taskar et al., "Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer," Clinical Cancer Research, vol. 16, no. 23, pp. 5664-5678, 2010.
26. W. Taal, H. M. Oosterkamp, A. M. E. Walenkamp et al., "Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial," The Lancet Oncology, vol. 15, no. 9, pp. 943-953, 2014.
27. Z. Tatar, E. Thivat, E. Planchat et al., "Temozolomide and unusual indications: review of literature," Cancer Treatment Reviews, vol. 39, no. 2, pp. 125-135, 2013.
28. R. Siegel, J. Ma, Z. Zou, and A. Jemal, "Cancer statistics, 2014," CA Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9-29, 2014.
29. P. W. Sperduto, M. Wang, H. I. Robins et al., "A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: radiationTherapy Oncology Group 0320," International Journal of Radiation Oncology Biology Physics, vol. 85, no. 5, pp. 1312-1318, 2013.
30. J. N. Greenspoon, W. Sharieff, H. Hirte et al., "Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study," OncoTargets and Therapy, vol. 7, pp. 485-490, 2014.
31. D. Bhojwani and C.-H. Pui, "Intrathecal liposomal cytarabine: more friend than foe?" Leukemia and Lymphoma, vol. 49, no. 8, pp. 1427-1430, 2008.
32. R. Parasole, G. Menna, N. Marra et al., "Efficacy and safety of intrathecal liposomal cytarabine for the treatment ofmeningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions," Leukemia and Lymphoma, vol. 49, no. 8, pp. 1553-1559, 2008.
33. N. Tomita, F. Kodama,H.Kanamori, S. Motomura, and Y. Ishigatsubo, "Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma," Cancer, vol. 95, no. 3, pp. 576-580, 2002.
34. W. J. Elias, D. Huss, T. Voss et al., "A pilot study of focused ultrasound thalamotomy for essential tremor,"TheNewEngland Journal of Medicine, vol. 369, no. 7, pp. 640-648, 2013.
35. N. Lipsman, M. L. Schwartz, Y. Huang et al., "MR-guided focused ultrasound thalamotomy for essential tremor: a proofof-concept study," The Lancet Neurology, vol. 12, no. 5, pp. 462-468, 2013.
36. C.-Y. Ting, C.-H. Fan, H.-L. Liu et al., "Concurrent bloodbrain barrier opening and local drug delivery using drugcarryingmicrobubbles and focused ultrasound for brain glioma treatment," Biomaterials, vol. 33, no. 2, pp. 704-712, 2012.
37. C. Y. Xia, Z. Zhang, Y. X. Xue, P. Wang, and Y. H. Liu, "Mechanisms of the increase in the permeability of the bloodbrain barrier obtained by combining low-frequency ultrasound irradiation with small-dose bradykinin," Journal of Neuro-Oncology, vol. 94, no. 1, pp. 41-50, 2009.
38. A. H. Mesiwala, L. Farrell, H. J. Wenzel et al., "High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo," Ultrasound in Medicine and Biology, vol. 28, no. 3, pp. 389-400, 2002.
39. T. Nhan, A. Burgess, E. E. Cho, B. Stefanovic, L. Lilge, and K. Hynynen, "Drug delivery to the brain by focused ultrasound induced blood-brain barrier disruption: quantitative evaluation of enhanced permeability of cerebral vasculature using twophoton microscopy," Journal of Controlled Release, vol. 172, no. 1, pp. 274-280, 2013.
40. C. C. Chen, P. S. Sheeran, S.-Y. Wu, O. O. Olumolade, P. A. Dayton, and E. E. Konofagou, "Targeted drug delivery with focused ultrasound-induced blood-brain barrier opening using acoustically-activated nanodroplets," Journal of Controlled Release, vol. 172, no. 3, pp. 795-804, 2013.
41. H.-L. Liu, C.-H. Fan, C.-Y. Ting, and C.-K. Yeh, "Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview," Theranostics, vol. 4, no. 4, pp. 432-444, 2014.
42. H.-L. Liu, H.-W. Yang, M.-Y. Hua, and K.-C. Wei, "Enhanced therapeutic agent delivery through magnetic resonance imaging-monitored focused ultrasound blood-brain barrier disruption for brain tumor treatment: an overview of the current preclinical status," Neurosurgical Focus, vol. 32, no. 1, article E4, 2012.
43. E. R. Cordeiro, X. Cathelineau, S. Thüroff, M. Marberger, S. Crouzet, and J. J. M. C. H. De La Rosette, "High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer," BJU International, vol. 110, no. 9, pp. 1228-1242, 2012.
44. K. F. Chu and D. E. Dupuy, "Thermal ablation of tumours: biological mechanisms and advances in therapy," Nature Reviews Cancer, vol. 14, no. 3, pp. 199-208, 2014.
45. M. Friedman, I. Mikityansky, A. Kam et al., "Radiofrequency ablation of cancer," CardioVascular and Interventional Radiology, vol. 27, no. 5, pp. 427-434, 2004.
46. S. McDermott and D. A. Gervais, "Radiofrequency ablation of liver tumors," Seminars in Interventional Radiology, vol. 30, no. 1, pp. 49-55, 2013.
47. M. G. Lubner, C. L. Brace, J. L. Hinshaw, and F. T. Lee Jr., "Microwave tumor ablation: mechanism of action, clinical results, and devices," Journal of Vascular and Interventional Radiology, vol. 21, no. 8, supplement, pp. S192-S203, 2010.
48. S. Jahangeer, P. Forde, D. Soden, and J. Hinchion, "Review of current thermal ablation treatment for lung cancer and the potential of electrochemotherapy as a means for treatment of lung tumours," Cancer Treatment Reviews, vol. 39, no. 8, pp. 862-871, 2013.
49. Y. F. Zhou, "High intensity focused ultrasound in clinical tumor ablation,"World Journal of Clinical Oncology, vol. 2, no. 1, pp. 8-27, 2011.
50. J. E. Kennedy, "High-intensity focused ultrasound in the treatment of solid tumours," Nature Reviews Cancer, vol. 5, no. 4, pp. 321-327, 2005.
51. H. Furusawa, K. Namba, H. Nakahara et al., "The evolving non-surgical ablation of breast cancer: MR guided focused ultrasound (MRgFUS)," Breast Cancer, vol. 14, no. 1, pp. 55-58, 2007.
52. R.O. Illing, J. E. Kennedy, F.Wu et al., "The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population," British Journal of Cancer, vol. 93, no. 8, pp. 890-895, 2005.
53. H. Lukka, T. Waldron, J. Chin et al., "High-intensity focused ultrasound for prostate cancer: a systematic review," Clinical Oncology, vol. 23, no. 2, pp. 117-127, 2011.
54. A. I. So, "HIFU ablation is not a proven standard treatment for localized prostate cancer," Journal of the Canadian Urological Association, vol. 5, no. 6, pp. 424-426, 2011.
55. S. Crouzet, J. Y. Chapelon, O. Rouvière et al., "Wholegland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients," European Urology, vol. 65, no. 5, pp. 907-914, 2014.
56. L. P. Luz, M. A. Al-Haddad, M. S. L. Sey, and J. M. Dewitt, "Applications of endoscopic ultrasound in pancreatic cancer," World Journal ofGastroenterology, vol. 20,no. 24,pp. 7808-7818, 2014.
57. R. Suzuki, A. Irisawa, and M. S. Bhutani, "Endoscopic ultrasound-guided oncologic therapy for pancreatic cancer," Diagnostic andTherapeutic Endoscopy, vol. 2013, Article ID 157581, 5 pages, 2013.
58. E. C. Verna and V. Dhar, "Review: endoscopic ultrasoundguided fine needle injection for cancer therapy: the evolving role of therapeutic endoscopic ultrasound," Therapeutic Advances in Gastroenterology, vol. 1, no. 2, pp. 103-109, 2008.
59. B. M. Yan and J. Van Dam, "Endoscopic ultrasound-guided intratumoural therapy for pancreatic cancer," Canadian Journal of Gastroenterology, vol. 22, no. 4, pp. 405-410, 2008.
60. W.-Y. Zhang, Z.-S. Li, and Z.-D. Jin, "Endoscopic ultrasoundguided ethanol ablation therapy for tumors," World Journal of Gastroenterology, vol. 19, no. 22, pp. 3397-3403, 2013.
61. S. Sun, H. Xu, J. Xin, J. Liu, Q. Guo, and S. Li, "Endoscopic ultrasound-guided interstitial brachytherapy of unresectable pancreatic cancer: results of a pilot trial," Endoscopy, vol. 38, no. 4, pp. 399-403, 2006.
62. H.-H.Chan,N. S.Nishioka,M.Mino et al., "EUS-guided photodynamic therapy of the pancreas: a pilot study," Gastrointestinal Endoscopy, vol. 59, no. 1, pp. 95-99, 2004.
63. T. E. Yusuf, K. Matthes, and W. R. Brugge, "EUS-guided photodynamic therapy with verteporfin for ablation of normal pancreatic tissue: a pilot study in a porcinemodel (with video)," Gastrointestinal Endoscopy, vol. 67, no. 6, pp. 957-961, 2008.
64. S. N. Goldberg, S. Mallery, G. S. Gazelle, and W. R. Brugge, "EUS-guided radiofrequency ablation in the pancreas: results in a porcine model," Gastrointestinal Endoscopy, vol. 50, no. 3, pp. 392-401, 1999.
65. M. Gaidhane, I. Smith, K. Ellen et al., "Endoscopic ultrasoundguided radiofrequency ablation (EUS-RFA) of the pancreas in a porcine model," Gastroenterology Research and Practice, vol. 2012, Article ID431451, 6 pages, 2012.
66. X. J. Wang, D. Mitchell, and T. J. Lewis, "Primary clinical use of sonodynamic therapy (SDT) for advanced breast cancer," Journal of Clinical Oncology, vol. 26, supplement 15, abstract 12029, 2008.
67. X.Wang,W. Zhang, Z. Xu, Y. Luo, D. Mitchell, and R.W.Moss, "Sonodynamic and photodynamic therapy in advanced breast carcinoma: a report of 3 cases," Integrative CancerTherapies, vol. 8, no. 3, pp. 283-287, 2009.
68. X.Wang, L. Q. Li,W. Zhang, Y. Luo, and D. G. Mitchell, "Sonodynamic and photodynamic therapy in advanced refractory breast cancer," Journal of Clinical Oncology, vol. 30, supplement 27, abstract 118, 2012.
69. L. Q. Li, X. Wang, I. W. Zhang, and D. Mitchell, "Primary clinical use of the sono-photo-dynamic therapy for advanced esophagocadiac and gastric adenocarcinoma," Journal of Clinical Oncology, vol. 32, supplement, abstract e15024, 2014.
70. M. Trendowski, "The inherent metastasis of leukaemia and its exploitation by sonodynamic therapy," Critical Reviews in Oncology/Hematology, vol. 94, no. 2, pp. 149-163, 2015.
71. T. deWitte, S. Suciu, G. Verhoef et al., "Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients withmyelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS," Blood, vol. 98, no. 8, pp. 2326-2331, 2001.
72. S. Dietrich, J.Weidle, M. Rieger et al., "Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma," Leukemia, vol. 28, no. 3, pp. 708-709, 2014.
73. T. Ramanathan and H. Skinner, "Coronary blood flow," Continuing Education in Anaesthesia, Critical Care and Pain, vol. 5, no. 2, pp. 61-64, 2005.
74. H. I. Bicher, F. W. Hetzel, T. S. Sandhu et al., "Effects of hyperthermia on normal and tumor microenvironment," Radiology, vol. 137, no. 2, pp. 523-530, 1980.
75. S. Shrivastav, W. G. Kaelin Jr., W. T. Joines, and R. L. Jirtle, "Microwave hyperthermia and its effect on tumor blood flow in rats," Cancer Research, vol. 43, no. 10, pp. 4665-4669, 1983.
76. H. Aoki, K. Kakinuma, K. Morita et al., "Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model," International Journal of Hyperthermia, vol. 20, no. 6, pp. 595-605, 2004.
77. A. M. Ponce, Z. Vujaskovic, F. Yuan, D. Needham, and M. W. Dewhirst, "Hyperthermia mediated liposomal drug delivery," International Journal of Hyperthermia, vol. 22, no. 3, pp. 205-213, 2006.
78. K. Morita, F. Zywietz, K. Kakinuma, R. Tanaka, and M. Katoh, "Efficacy of doxorubicin thermosensitive liposomes (40°C) and local hyperthermia on rat rhabdomyosarcoma," Oncology Reports, vol. 20, no. 2, pp. 365-372, 2008.
79. E. L. Jones, T. V. Samulski, M. W. Dewhirst et al., "A pilot phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma," Cancer, vol. 98, no. 2, pp. 277-282, 2003.
80. G. P. Raaphorst, J. Maio, C. E. Ng, and D. J. Stewart, "Concomitant treatment with mild hyperthermia, cisplatin and low dose-rate irradiation in human ovarian cancer cells sensitive and resistant to cisplatin," Oncology Reports, vol. 5, no. 4, pp. 971-977, 1998.
81. J. W. J. Bergs, J. Haveman, R. Ten Cate, J. P. Medema, N. A. P. Franken, and C. Van Bree, "Effect of 41°C and 43°C on cisplatin radiosensitization in two human carcinoma cell lines with different sensitivities for cisplatin," Oncology Reports, vol. 18, no. 1, pp. 219-226, 2007.
82. G. A. Koning, A. M. M. Eggermont, L. H. Lindner, and T. L.M. ten Hagen, "Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors," Pharmaceutical Research, vol. 27, no. 8, pp. 1750-1754, 2010.
83. G. Kong, G. Anyarambhatla, W. P. Petros et al., "Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release," Cancer Research, vol. 60, no. 24, pp. 6950-6957, 2000.
84. C. J. Diederich and K. Hynynen, "Ultrasound technology for hyperthermia," Ultrasound in Medicine and Biology, vol. 25, no. 6, pp. 871-887, 1999.
85. Q.-Q. Meng, B.-A. Chen, W. Wu, Z.-Y. Shao, F. Gao, and H.-H. Zhao, "Antitumor effects of low-frequency ultrasound combined with adriamycin on human leukemia multidrug resistance cell line K562/A02," Chinese Journal of Cancer, vol. 27, no. 11, pp. 436-439, 2008.
86. Y.-Z. Zhao, C.-T. Lu, Z.-C. Zhou et al., "Enhancing chemotherapeutic drug inhibition on tumor growth by ultrasound: an in vivo experiment," Journal of Drug Targeting, vol. 19, no. 2, pp. 154-160, 2011.
87. T. Yoshida, T. Kondo, R. Ogawa et al., "Combination of doxorubicin and low-intensity ultrasound causes a synergistic enhancement in cell killing and an additive enhancement in apoptosis induction in human lymphoma U937 cells," Cancer Chemotherapy and Pharmacology, vol. 61, no. 4, pp. 559-567, 2008.
88. L. Liang, S. Xie, L. Jiang, H. Jin, S. Li, and J. Liu, "The Combined effects of hematoporphyrin monomethyl ether-SDT and doxorubicin on the proliferation of QBC939 cell lines," Ultrasound in Medicine and Biology, vol. 39, no. 1, pp. 146-160, 2013.
89. M. Trendowski, G. Yu, V.Wong, C. Acquafondata, T. Christen, and T. P. Fondy, "The real deal: using cytochalasin B in sonodynamic therapy to preferentially damage leukemia cells," Anticancer Research, vol. 34, no. 5, pp. 2195-2202, 2014.
90. M. Trendowski, V. Wong, J. N. Zoino et al., "Preferential enlargement of leukemia cells using cytoskeletal-directed agents and cell cycle growth control parameters to induce sensitivity to low frequency ultrasound," Cancer Letters, vol. 360, no. 2, pp. 160-170, 2015.
91. M.Trendowski, J.M.Mitchell,C.M.Corsette, C. Acquafondata, and T. P. Fondy, "Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models," Investigational New Drugs, vol. 33, no. 2, pp. 290-299, 2015.
92. F. J. O'Neill, "Selective destruction of cultured tumor cells with uncontrolled nuclear division by cytochalasin B and cytosine arabinoside," Cancer Research, vol. 35, no. 11, part 1, pp. 3111-3115, 1975.
93. M. J. Semins, B. J. Trock, and B. R.Matlaga, "The effect of shock wave rate on the outcome of shock wave lithotripsy: a metaanalysis," Journal of Urology, vol. 179, no. 1, pp. 194-197, 2008.
94. K. T. Pace, D. Ghiculete, M. Harju, and R. J. D. Honey, "Shock wave lithotripsy at 60 or 120 shocks per minute: a randomized, double-blind trial," Journal of Urology, vol. 174, no. 2, pp. 595-599, 2005.
95. M. Trendowski, V.Wong, G. Yu, and T. P. Fondy, "Enlargement and multinucleation of U937 leukemia and MCF7 breast carcinoma cells by antineoplastic agents to enhance sensitivity to low frequency ultrasound and to DNA-directed anticancer agents," Anticancer Research, vol. 35, no. 1, pp. 65-76, 2015.
96. B. Zhai, L. Chen, Y. Guo, Z.Wang, and F.Wu, "Experimental study of ultrasound onMDR in a human tumor in vivo," Chinese Journal of Clinical Oncology, vol. 4, no. 6, pp. 390-396, 2007.
97. M. A. Kolber and P. Hill, "Vincristine potentiates cytochalasin B-induced DNA fragmentation in vitro," Cancer Chemotherapy and Pharmacology, vol. 30, no. 4, pp. 286-290, 1992.
98. P. Mehlen and A. Puisieux, "Metastasis: a question of life or death," Nature Reviews Cancer, vol. 6, no. 6, pp. 449-458, 2006.
99. D. Spano, C. Heck, P. De Antonellis, G. Christofori, and M. Zollo, "Molecular networks that regulate cancer metastasis," Seminars in Cancer Biology, vol. 22, no. 3, pp. 234-249, 2012.
100. S. Valastyan and R. A.Weinberg, "Tumormetastasis:molecular insights and evolving paradigms," Cell, vol. 147, no. 2, pp. 275-292, 2011.
101. S. Tinkov, C. Coester, S. Serba et al., "New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: in-vivo characterization," Journal of Controlled Release, vol. 148, no. 3, pp. 368-372, 2010.
102. Z. Deng, F. Yan, Q. Jin et al., "Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicinliposome-microbubble complexes assisted by ultrasound," Journal of Controlled Release, vol. 174, no. 1, pp. 109-116, 2014.
103. M. Todorova, V. Agache, O.Mortazavi et al., "Antitumor effects of combining metronomic chemotherapy with the antivascular action of ultrasound stimulated microbubbles," International Journal of Cancer, vol. 132, no. 12, pp. 2956-2966, 2013.
104. H. Tsuru, H. Shibaguchi, M. Kuroki, Y. Yamashita, and M. Kuroki, "Tumor growth inhibition by sonodynamic therapy using a novel sonosensitizer," Free Radical Biology andMedicine, vol. 53, no. 3, pp. 464-472, 2012.
105. D. E. Goertz, M. Todorova, O. Mortazavi et al., "Antitumor effects of combining docetaxel (taxotere) with the antivascular action of ultrasound stimulated microbubbles," PLoS ONE, vol. 7, no. 12, Article ID e52307, 2012.
106. N. Yumita, N. Okuyama, K. Sasaki, and S.-I. Umemura, "Sonodynamic therapy on chemically induced mammary tumor: pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of porfimer sodium," Cancer Science, vol. 95, no. 9, pp. 765-769, 2004.
107. Z. Gao, J. Zheng, B. Yang et al., "Sonodynamic therapy inhibits angiogenesis and tumor growth in a xenograft mouse model," Cancer Letters, vol. 335, no. 1, pp. 93-99, 2013.
108. A. Sazgarnia, A. Shanei, N. T. Meibodi, H. Eshghi, and H. Nassirli, "A novel nanosonosensitizer for sonodynamic therapy: in vivo study on a colon tumor model," Journal of Ultrasound in Medicine, vol. 30, no. 10, pp. 1321-1329, 2011.
109. F. Nie, H.-X. Xu, M.-D. Lu, Y. Wang, and Q. Tang, "Antiangiogenic gene therapy for hepatocellular carcinomamediated by microbubble-enhanced ultrasound exposure: an in vivo experimental study," Journal of Drug Targeting, vol. 16, no. 5, pp. 389-395, 2008.
110. J. Škorpíková, M. Dolníková, I. Hrazdira, and R. Janisch, "Changes in microtubules and microfilaments due to a combined effect of ultrasound and cytostatics in HeLa cells," Folia Biologica, vol. 47, no. 4, pp. 143-147, 2001.
111. W.-S. Chen, A. A. Brayman, T. J. Matula, L. A. Crum, and M. W. Miller, "The pulse length-dependence of inertial cavitation dose and hemolysis," Ultrasound in Medicine and Biology, vol. 29, no. 5, pp. 739-748, 2003.
112. H.Ando, L. B. Feril Jr.,T.Kondo et al., "An echo-contrast agent, Levovist, lowers the ultrasound intensity required to induce apoptosis of human leukemia cells," Cancer Letters, vol. 242, no. 1, pp. 37-45, 2006.
113. X. Su, P. Wang, X. Wang, B. Cao, L. Li, and Q. Liu, "Apoptosis of U937 cells induced by hematoporphyrin monomethyl ethermediated sonodynamic action," Cancer Biotherapy and Radiopharmaceuticals, vol. 28, no. 3, pp. 207-217, 2013.